1. Home
  2. POM vs MBAI Comparison

POM vs MBAI Comparison

Compare POM & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

POM

POMDOCTOR LIMITED American Depositary Shares

N/A

Current Price

$0.11

Market Cap

13.5M

ML Signal

N/A

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.68

Market Cap

12.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
POM
MBAI
Founded
2015
2004
Country
China
Israel
Employees
N/A
85
Industry
Other Specialty Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
13.5M
12.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
POM
MBAI
Price
$0.11
$1.68
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
18.6M
151.3K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$1.29
52 Week High
$6.43
$3.92

Technical Indicators

Market Signals
Indicator
POM
MBAI
Relative Strength Index (RSI) 36.39 49.46
Support Level $0.06 $1.35
Resistance Level $0.43 $1.91
Average True Range (ATR) 0.09 0.18
MACD -0.01 0.02
Stochastic Oscillator 8.36 40.00

Price Performance

Historical Comparison
POM
MBAI

About POM POMDOCTOR LIMITED American Depositary Shares

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: